169 related articles for article (PubMed ID: 33049098)
1. Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol-3-kinase (PI3K): Current and Future Prospects.
Rodrigues DA; Pinheiro PSM; Fraga CAM
ChemMedChem; 2021 Feb; 16(3):448-457. PubMed ID: 33049098
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Pharmacological Evaluation of First-in-Class Multitarget N-Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors.
Rodrigues DA; Guerra FS; Sagrillo FS; de Sena M Pinheiro P; Alves MA; Thota S; Chaves LS; Sant'Anna CMR; Fernandes PD; Fraga CAM
ChemMedChem; 2020 Mar; 15(6):539-551. PubMed ID: 32022441
[TBL] [Abstract][Full Text] [Related]
3. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
4. Current status in the discovery of dual BET/HDAC inhibitors.
Ren Q; Gao W
Bioorg Med Chem Lett; 2021 Jan; 31():127671. PubMed ID: 33229136
[TBL] [Abstract][Full Text] [Related]
5. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach.
Ranganna K; Selvam C; Shivachar A; Yousefipour Z
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33147762
[TBL] [Abstract][Full Text] [Related]
6. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
Tseng HJ; Lin MH; Shiao YJ; Yang YC; Chu JC; Chen CY; Chen YY; Lin TE; Su CJ; Pan SL; Chen LC; Wang CY; Hsu KC; Huang WJ
Eur J Med Chem; 2020 Apr; 192():112193. PubMed ID: 32151835
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
Zhang K; Lai F; Lin S; Ji M; Zhang J; Zhang Y; Jin J; Fu R; Wu D; Tian H; Xue N; Sheng L; Zou X; Li Y; Chen X; Xu H
J Med Chem; 2019 Aug; 62(15):6992-7014. PubMed ID: 31117517
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
10. Histone Deacetylase Inhibitors as Multitarget Ligands: New Players in Alzheimer's Disease Drug Discovery?
De Simone A; Milelli A
ChemMedChem; 2019 Jun; 14(11):1067-1073. PubMed ID: 30958639
[TBL] [Abstract][Full Text] [Related]
11. From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
Qiu X; Zhu L; Wang H; Tan Y; Yang Z; Yang L; Wan L
Bioorg Med Chem; 2021 Dec; 52():116510. PubMed ID: 34826681
[TBL] [Abstract][Full Text] [Related]
12. Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles.
Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Tan H; Wu W; Xu M; Pineda-Lucena A; Garcia-Osta A; Oyarzabal J
ACS Chem Neurosci; 2019 Sep; 10(9):4076-4101. PubMed ID: 31441641
[TBL] [Abstract][Full Text] [Related]
13. Innovative Strategies for Selective Inhibition of Histone Deacetylases.
Maolanon AR; Madsen AS; Olsen CA
Cell Chem Biol; 2016 Jul; 23(7):759-768. PubMed ID: 27447046
[TBL] [Abstract][Full Text] [Related]
14. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
Hu C; Xia H; Bai S; Zhao J; Edwards H; Li X; Yang Y; Lyu J; Wang G; Zhan Y; Dong Y; Ge Y
J Cell Mol Med; 2020 Jul; 24(13):7239-7253. PubMed ID: 32459381
[TBL] [Abstract][Full Text] [Related]
15. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
16. Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K/c-Myc axis on panobinostat cytotoxicity.
Zehtabcheh S; Yousefi AM; Salari S; Safa M; Momeny M; Ghaffari SH; Bashash D
Cell Biol Int; 2021 May; 45(5):1111-1121. PubMed ID: 33501756
[TBL] [Abstract][Full Text] [Related]
17. Inside HDAC with HDAC inhibitors.
Bertrand P
Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Computer-Assisted Structure-Based Identification and Design of Histone Deacetylases Inhibitors.
Krishna S; Kumar V; Siddiqi MI
Curr Top Med Chem; 2016; 16(9):934-47. PubMed ID: 26303428
[TBL] [Abstract][Full Text] [Related]
19. Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review.
Wang Y; Tortorella M
Eur J Med Chem; 2022 Jan; 228():114039. PubMed ID: 34894440
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
Liu S; Zhao S; Dong Y; Wang T; Niu X; Zhao L; Wang G
Cancer Chemother Pharmacol; 2021 Mar; 87(3):415-423. PubMed ID: 33392641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
